Kymberley L Sutton

Title: Kymberley L Sutton: Innovator in Monocyte Activation Modulation

Introduction

Kymberley L Sutton is a notable inventor based in Surrey, Canada. She has made significant contributions to the field of immunology, particularly in the modulation of monocyte activation. Her innovative work has the potential to impact therapeutic strategies for inflammatory diseases.

Latest Patents

Kymberley L Sutton holds a patent titled "Integrin linked kinase modulation of monocyte activation." This patent describes methods to specifically modulate the activation of monocytes and/or macrophages. The administration of integrin linked kinase (ILK) blocking agents, compounds that prevent the binding of natural ILK ligands to ILK, or compounds that inhibit ILK expression or signaling, exerts an anti-inflammatory effect. This is achieved by inhibiting iNOS and COX-2 expression at the transcription level by suppressing the activation of NF-κB. The modulation of activation through ILK is utilized to regulate immune processes at targeted sites, aiming to decrease undesirable inflammatory responses.

Career Highlights

Kymberley L Sutton is associated with QLT Inc., where she continues to advance her research and development efforts. Her work is characterized by a commitment to understanding and manipulating immune responses, which is crucial for developing new therapeutic approaches.

Collaborations

Kymberley collaborates with notable colleagues, including Patricia M Logan and Gabriel Bela Kalmar. These collaborations enhance her research capabilities and contribute to the innovative environment at QLT Inc.

Conclusion

Kymberley L Sutton's contributions to the field of immunology through her patent on monocyte activation modulation highlight her role as an influential inventor. Her work not only advances scientific understanding but also holds promise for future therapeutic applications.